Cefditoren Dosage
This dosage information may not include all the information needed to use Cefditoren safely and effectively. See additional information for Cefditoren.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Usual Adult Dose for:
Usual Pediatric Dose for:
Additional dosage information:
Usual Adult Dose for Bronchitis
Acute bacterial exacerbation of chronic bronchitis: 400 mg orally twice a day for 10 days
Usual Adult Dose for Pneumonia
Community-acquired: 400 mg orally twice a day for 14 days
Usual Adult Dose for Tonsillitis/Pharyngitis
200 mg orally twice a day for 10 days
Usual Adult Dose for Skin or Soft Tissue Infection
Uncomplicated: 200 mg orally twice a day for 10 days
Usual Pediatric Dose for Bronchitis
12 years or older:
Acute bacterial exacerbation of chronic bronchitis: 400 mg orally twice a day for 10 days
Usual Pediatric Dose for Pneumonia
12 years or older:
Community-acquired: 400 mg orally twice a day for 14 days
Usual Pediatric Dose for Tonsillitis/Pharyngitis
12 years or older: 200 mg orally twice a day for 10 days
Usual Pediatric Dose for Skin and Structure Infection
12 years or older:
Uncomplicated: 200 mg orally twice a day for 10 days
Renal Dose Adjustments
CrCl 30 to 49 mL/min: Not more than 200 mg orally twice a day
CrCl 29 mL/min or less: 200 mg orally once a day
End-stage renal disease: Data not available
Liver Dose Adjustments
No adjustment recommended.
Precautions
Cefditoren is contraindicated in persons with carnitine deficiency or metabolic disorders that may result in clinically significant deficiency, because the drug causes renal excretion of carnitine.
Not recommended for prolonged use because other pivalate-containing compounds have caused clinical manifestations of carnitine deficiency when used over period of months. Short-term treatment of cefditoren pivoxil has not been associated with clinical effects of decreased carnitine levels.
Serious and occasionally fatal hypersensitivity reactions have been reported with antibiotics. The drug should be discontinued immediately at the first appearance of a skin rash or other signs of hypersensitivity. Severe, acute hypersensitivity reactions may require treatment with epinephrine and other resuscitative measures including oxygen, intravenous fluids, antihistamines, corticosteroids, cardiovascular support and airway management as clinically indicated.
Do not give to patients with milk protein hypersensitivity (not lactose intolerance), because the tablet formulation contains sodium caseinate, a milk protein.
Clostridium difficile associated diarrhea (CDAD) has been reported with almost all antibiotics and may potentially be life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea following cephalosporin therapy. Mild cases generally improve with discontinuation of the drug, while severe cases may require supportive therapy and treatment with an antimicrobial agent effective against C difficile. Hypertoxin producing strains of C difficile cause increased morbidity and mortality; these infections can be resistant to antimicrobial treatment and may necessitate colectomy.
Cephalosporins may be associated with a fall in prothrombin activity. Risk factors include renal or hepatic impairment, poor nutritional state, a protracted course of antimicrobial therapy, and chronic anticoagulation therapy. Prothrombin times should be monitored and vitamin K therapy initiated if indicated.
Some cephalosporins have been associated with seizures in renally impaired patients with elevated serum concentrations. The drug should be discontinued if seizures occur. Renal function should be monitored, especially in elderly patients.
To reduce the risk of development of drug resistant organisms, antibiotics should only be used to treat or prevent proven or suspected infections caused by bacteria. Culture and susceptibility information should be considered when selecting treatment or, if no data are available, local epidemiology and susceptibility patterns may be considered when selecting empiric therapy. Patients should be advised to avoid missing doses and to complete the entire course of therapy.
Cefditoren is not recommended for patients under 12 years. Safety and efficacy have not been established in this population.
Dialysis
30% of cefditoren was removed by hemodialysis (4 hours duration) without any changes to terminal half-life
Other Comments
Should be taken with meals for optimal absorption
